{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:31:06Z","timestamp":1781587866922,"version":"3.54.5"},"reference-count":131,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p>Docetaxel is a semisynthetic taxane indicated for the treatment of advanced breast, prostate, and non\u2013small cell lung cancers; it is also used for the treatment of various other solid tumors. The standard intermittent dosage of docetaxel is 60\u2013100 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks. At this dose and schedule, myelosuppression is common and neutropenia is usually the dose\u2010limiting toxicity. Weekly administration of docetaxel 20\u201342 mg\/m<jats:sup>2<\/jats:sup> is being tested in the treatment of advanced solid tumors in order to improve patient tolerance by reducing the interval dose and to maintain therapeutic efficacy by increasing overall dose intensity. Asthenia and peripheral neuropathy can limit continued administration of weekly docetaxel. Epiphora (excess tearing due to narrowing or blockage of the lacrimal outflow passages) is associated with repeated weekly administration of docetaxel. This adverse effect can interfere with activities of daily life and negatively affect quality of life. Epiphora may be an underreported adverse effect of treatment because of underrecognition by clinicians and patient embarrassment with respect to seemingly uncontrolled tearing. The use of weekly docetaxel administration is expanding; therefore, patients should be educated to recognize and report signs and symptoms of epiphora. It is important for clinicians participating in the care of patients undergoing treatment with docetaxel to monitor for excess tearing and signs of eye irritation to ensure timely management of treatment\u2010related epiphora.<\/jats:p>","DOI":"10.1592\/phco.26.6.853","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:14:16Z","timestamp":1148303656000},"page":"853-867","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Docetaxel\u2010Associated Epiphora"],"prefix":"10.1002","volume":"26","author":[{"given":"Polly E.","family":"Kintzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne K.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Taxotere (docetaxel injection concentrate) package insert","author":"Aventis Pharmaceuticals, Inc.","year":"2004"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.6.1593"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.08.031"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.310"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00072-1"},{"key":"e_1_2_1_7_2","first-page":"837","article-title":"Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum","volume":"2","author":"Kavanagh J.J.","year":"1996","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh323"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1853"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2341"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.046"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1413"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02665349"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200304000-00005"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.2000.18.6.1346","article-title":"Phase II trial of docetaxel and vinorelbine in patients with advanced non\u2010small\u2010cell lung cancer","volume":"18","author":"Miller V.A.","year":"2000","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.08.021"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1212"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg456"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02967619"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3500"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10101-0"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012557528952"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf027"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000184"},{"key":"e_1_2_1_25_2","first-page":"1047","article-title":"Weekly taxanes in metastatic breast cancer (review)","volume":"9","author":"Zimatore M.","year":"2002","journal-title":"Oncol Rep"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008399712913"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.028"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065060"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00185-X"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyh021"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10991"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000082628"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hye019"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi207"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0909-8"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.2.192"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6786"},{"key":"e_1_2_1_38_2","first-page":"1698","article-title":"Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non\u2010small cell lung cancer: a phase I study","volume":"9","author":"Wirth L.J.","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_39_2","first-page":"1479","article-title":"Protracted administration of weekly docetaxel in metastatic breast cancer","volume":"10","author":"Kuroi K.","year":"2003","journal-title":"Oncol Rep"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)00989-2"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.016"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120022373"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00640-0"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11527"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006324-200304000-00004"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh349"},{"key":"e_1_2_1_49_2","first-page":"1923","article-title":"Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?","volume":"23","author":"Maisano R.","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_1_50_2","first-page":"19","volume-title":"Anatomical chart series","author":"Anonymous","year":"1993"},{"key":"e_1_2_1_51_2","volume-title":"Ophthalmology","author":"Hurwitz J.J.","year":"2004"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)60013-X"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701415"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602241"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi018"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.621"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.058"},{"key":"e_1_2_1_58_2","first-page":"1301","article-title":"Weekly intravenous recombinant humanized anti\u2010p185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study","volume":"21","author":"Meden H.","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_1_59_2","first-page":"686","article-title":"Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study","volume":"9","author":"Est\u00e9vez L.G.","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0634"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11738"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1727"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(01)00402-0"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008373814453"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.074"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1021-03"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.22.030"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000075016.29682.E0"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf036"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1891\/vivi.2003.18.5.533"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-3514.74.3.686"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.9.1180"},{"key":"e_1_2_1_74_2","first-page":"2175","volume-title":"Drug facts and comparisons 2005","author":"Reilly C.H.","year":"2005"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0476-9"},{"key":"e_1_2_1_76_2","first-page":"1470","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Hardman J.G.","year":"1996"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.12.1802"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0842-03"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2004.09.007"},{"key":"e_1_2_1_80_2","first-page":"1557","volume-title":"Cancer: principles and practice of oncology","author":"Harris J.R.","year":"1997"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.187"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050032"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.09.005"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2391::AID-CNCR1587>3.0.CO;2-M"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089160409000112"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.05.015"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0810-5"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(01)00328-2"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00027-8"},{"key":"e_1_2_1_91_2","first-page":"1211","article-title":"Weekly docetaxel as second\u2010line chemotherapy in advanced non\u2010small cell lung cancer: phase II trial","volume":"24","author":"Serke M.","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh015"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-003-1039-5"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20281"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.117"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012258723075"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11687"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.08.022"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078328"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1159\/000070285"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-005-1272-3"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)01370-1"},{"key":"e_1_2_1_104_2","first-page":"4771","article-title":"Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma: a preliminary report of tolerance and local control","volume":"17","author":"Varveris H.","year":"1997","journal-title":"Anticancer Res"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf017"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074474"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.1.85"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.163"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(18)30188-5"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.082"},{"key":"e_1_2_1_111_2","volume-title":"Cancer facts and figures","author":"American Cancer Society","year":"2005"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811001)48:7<1539::AID-CNCR2820480713>3.0.CO;2-B"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000066648.33513.3D"},{"key":"e_1_2_1_114_2","volume-title":"Eloxatin (oxaliplatin injection) package insert","author":"Sanofi\u2010Synthelabo, Inc.","year":"2005"},{"key":"e_1_2_1_115_2","volume-title":"Nipent (pentostatin for injection) package insert","author":"Supergen, Inc.","year":"1998"},{"key":"e_1_2_1_116_2","volume-title":"Trisenox (arsenic trioxide injection) package insert","author":"Cephalon, Inc.","year":"2003"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830201)51:3<430::AID-CNCR2820510313>3.0.CO;2-5"},{"key":"e_1_2_1_118_2","volume-title":"Ellence (epirubicin hydrochloride injection) package insert","author":"Pfizer, Inc.","year":"2005"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262591"},{"key":"e_1_2_1_120_2","first-page":"2282","volume-title":"Drug facts and comparisons 2005","author":"Novak K.K.","year":"2005"},{"key":"e_1_2_1_121_2","volume-title":"ThioTEPA for injection, USP package insert","author":"Sicor Pharmaceuticals, Inc.","year":"2004"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078001110.x"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01203288"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-89-4-574_1"},{"key":"e_1_2_1_125_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jama.1973.03220340051021","article-title":"Excessive lacrimation from fluorouracil treatment","volume":"225","author":"Hamersley J.","year":"1973","journal-title":"JAMA"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-88-5-657_1"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1998.83"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(82)90006-X"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(81)90240-3"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.93"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911015)68:8<1691::AID-CNCR2820680805>3.0.CO;2-W"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808702101007"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.6.853","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.6.853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:32:34Z","timestamp":1761064354000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.6.853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1592\/phco.26.6.853"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.6.853","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}